As the race to deliver advanced gene therapies accelerates, AAV production must keep pace—with no room for inconsistency. This article dives into how high-performance cell culture media is unlocking new levels of reliability, scalability, and yield in AAV manufacturing.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
By submitting this form, you consent to Cell & Gene Therapy Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.